These are the posts from the How we think section that have been tagged with Chronic Illness.
To see all tags used in our posts, click here.
| 22nd February 2017
Founded by Michael Seres in 2011, 11 Health is a connected medical device company currently working to change the lives of patients using stoma bags. Content Marketing Manager Liz Inskip interviews Michael about how patients are changing the role of the expert in healthcare, and the systematic barriers to innovation in healthcare.
| 18th January 2017
Content Marketing Manager Liz Inskip interviews Neil Maiden of City, University of London, about his work developing mobile technology solutions for residential dementia care, and what the challenges facing innovators in this therapy area are.
| 16th November 2016
Account Executive Victoria Morton explores what it’s like to live with Crohn’s disease as a young person, and investigates what’s being done to tackle the gaps in treatment options for patients.
| 2nd September 2016
Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.
| 19th July 2016
In the last 13 years, only one new drug has been approved for patients with Alzheimer's Disease. The most recently approved drug was in 2014, bringing the total number of agents approved across AD to 5. In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as look at the some of the glimmers of light at the end of the tunnel.
| 19th May 2016
Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.
| 23rd September 2015
Recently, Blue Latitude Health worked with a global pharmaceutical brand to develop a strategy for dealing with the introduction of biosimilars to the market. Their product, a treatment in the gastroenterology therapy area, had recently come off patent and a biosimilar was about to launch. Strategy Consultant Mark Assenti talks through three key points for developing a strategy to tackle biosimilars.
| 24th June 2015
Director and Head of Commercial Simon takes us through some of the key themes of the Financial Times Digital Health Summit in London, outlining and expanding on where we feel the industry is heading as we get closer to the ‘digital health revolution’.